A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor–dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2

Cancer Immunology, Immunotherapy

Volumn 65, Issue 4, 2016, Pages 383-392

  Greene, Julia M ^a   Schneble, Erika J ^a   Jackson, Doreen O ^a   Hale, Diane F ^a   Vreeland, Timothy J ^a   Flores, Madeline ^a   Martin, Jonathan ^a   Herbert, Garth S ^a   Hardin, Mark O ^b   Yu, Xianzhong ^c   Wagner, Thomas E ^d   Peoples, George E ^e,f  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^b MADIGAN ARMY MEDICAL CENTER   (United States)

^c CLEMSON UNIVERSITY   (United States)

^d Perseus PCI   (United States)

^e Cancer Vaccine Development Program   (United States)

^f Uniformed Services University of the Health Sciences   (United States)

Author keywords

Adjuvant; Dendritic cell; Dendritoma; Melanoma; Vaccine

Indexed keywords

CANCER VACCINE; DENDRITOMA VACCINE; INTERLEUKIN 2; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STAGING; CARDIOVASCULAR DISEASE; CHILL; CLINICAL ARTICLE; DENDRITIC CELL; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; EDEMA; ERYTHEMA; FEMALE; FEVER; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL DISEASE; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPOTENSION; HYPOXIA; INFECTION; MALE; MELANOMA; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN BRUISING; SKIN MANIFESTATION; SKIN TOXICITY; STOMATITIS; SWELLING; SYSTEMIC DISEASE; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; WEIGHT GAIN; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; TUMOR RECURRENCE;

AGED; ARTHRALGIA; CANCER VACCINES; CHILLS; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHEMA; FEMALE; HUMANS; INTERLEUKIN-2; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; NAUSEA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 84964009653     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1809-6     Document Type: Article

References (51)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30
2. Miller AJ, Mihm MC Jr (2006) Melanoma. N Engl J Med 355(1):51–65
3. Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351(10):998–1012
4. Sasse AD, Sasse EC, Clark LG, Ulloa L, Clark OA (2007) Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 1:CD005413
5. Atkins MB, Kunkel L, Sznol M, Rosenberg SA (2000) High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6(Suppl 1):S11–S14
6. Keilholz U, Punt CJ, Gore M et al (2005) Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European organisation for research and treatment of cancer melanoma group. J Clin Oncol 23(27):6747–6755
7. Naidoo J, Page DB, Wolchok JD (2014) Immune checkpoint blockade. Hematol Oncol Clin North Am 28(3):585–600
8. Sharma P, Wagner K, Wolchok JD, Allison JP (2011) Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 11(11):805–812
9. Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723
10. Robert C, Ribas A, Wolchok JD et al (2014) Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparsion cohort of a phase 1 trial. Lancet 384(9948):1109–1117
11. Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320–330
12. Robert C, Thomas L, Bondarenko I et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526
13. Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122–133
14. Ott PA, Hodi FS, Robert C (2013) CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 19(19):5300–5309
15. McDermott D, Haanen J, Chen TT, Lorigan P, O’Day S, Investigators MDX (2013) Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Ann Oncol 24(10):2694–2698
16. Hamid O, Robert C, Daud A et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369(2):134–144
17. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–422
18. Kantoff PW, Schuetz TJ, Blumenstein BA et al (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28(7):1099–1105
19. Schneble EJ, Yu X, Wagner T, Peoples GE (2014) Novel dendritic cell-based vaccination in late stage melanoma. Human Vaccines Immunother 10(11):3132–3138
20. Holmes LM, Li J, Sticca RP, Wagner TE, Wei Y (2001) A rapid, novel strategy to induce tumor cell-specific cytotoxic T lymphocyte responses using instant dentritomas. J Immunother 24(2):122–129
21. Gong J, Chen D, Kufe D (1997) Induction of antitumor activity by immunization with fusions of dendritic carcinoma cells. Nat Med 3:558–561
22. Wang J, Saffold S, Cao X et al (1998) Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 161:5516–5524
23. Lespagnard L, Mettens P, Verheyden A et al (1998) Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int J Cancer 76:250–258
24. Cao X, Zhang W, Wang J et al (1999) Therapy of established tumor with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells. Immunology 97:616–625
25. Wei Y, Sticca RP, Holmes LM et al (2006) Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int J Oncol 28(3):585–593
26. Wei YC, Sticca RP, Li J et al (2007) Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: a pilot study. Oncol Rep 18(3):665–671
27. Mahoney KM, Freeman GJ, McDermott DF (2015) The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther 37(4):764–782
28. Postow MA, Chesney J, Pavlick AC et al (2015) Novolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006–2017
29. Wasif N, Bagaria S, Ray P, Morton D (2011) Does metastectomy improve survival in patients with stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol 104(2):111–115
30. Kaufman HL (2012) Vaccines for melanoma and renal cell carcinoma. Semin Oncol 39:263–275
31. Klein O, Schmidt C, Knights A et al (2011) Melanoma vaccines: developments over the past 10 years. Expert Rev Vaccines 10:853–873
32. Kawakami Y, Robbins PF, Wang RF et al (1998) The use of melanosomal proteins in the immunotherapy of melanoma. J Immunother 21:237–246
33. Slingluff CL Jr, Petroni GR, Yamshchikov GV et al (2003) Clinical and immunologic results of a randomized phase II trial of vaccination using four peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21:4016–4026
34. Slingluff CL Jr, Petroni GR, Olson WC et al (2009) Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multi-peptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 15:7036–7044
35. Block MS, Suman VJ, Nevala WK et al (2011) Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine. Melanoma Res 21:438–445
36. Kruit WH, van Ojik HH, Brichard VG et al (2005) Phase I/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 117:596–604
37. Kruit WH, Suciu S, Dreno B et al (2013) Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European organisation for research and treatment of cancer melanoma group in metastatic melanoma. J Clin Oncol 31:2413–2421
38. Sabado RL, Pavlick AC, Gnjatic S, et al (2012) Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma. ASCO Annual Meeting Abstracts. J Clin Oncol 30:Abstract 2589
39. Weiss SA, Chandra S, Pavlick AC (2014) Update on vaccine for high-risk melanoma. Curr Treat Options Oncol 15:269–280
40. Kirkwood JM, Dreno B, Hauschild A, et al. (2011) DERMA phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3-positive resected stage III melanoma. ASCO Annual Meeting Abstracts. J Clin Oncol 29:Suppl Abstract TPS232
41. Eggermont AMM, Suciu S, Rutkowski P et al (2013) Adjuvant ganglioside GM2-KLH/QS-21 vaccination vs observation after resection of primary tumor 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. J Clin Oncol 31:3831–3840
42. Morton DL, Hseuh EC, Essner R et al (2002) Prolonged survival of patients receiving active immunotherapy with canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 236:438–449
43. Hsueh EC, Essner R, Foshag LJ et al (2002) Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 20:4549–4554
44. Tsioulias GJ, Gupta RK, Tisman G et al (2001) Serum TA90 Antigen-antibody complex as a surrogate marker for the efficacy of a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma. Ann Surg Oncol 8:198–203
45. Mackiewic A, Mackiewicz J, Wysocki PJ et al (2012) Longterm survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection. Expert Opin Investig Drugs 21:773–783
46. Markowicz S, Nowecki ZI, Rutkowski P et al (2012) Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients. Med Oncol 29:2966–2977
47. Petenko NN, Mikhaylova IN, Chkadua GZ et al (2012) Adjuvant dendritic cell (DC)-based vaccine therapy of melanoma patients. ASCO Annual Meeting Abstracts. J Clin Oncol. 30:Abstract 2524
48. Andtbacka RHI, Collichio F, Amatruda T, et al. (2013) OPTIM: a randomized phase 3 trial of talimogene laherparepvec (T-VEC) vs subcutaneous granulocyte macrophage colony-stimulating factor for the treatment of unresectable stage IIIB/C and IV melanoma. ASCO Annual Meeting Abstracts. J Clin Oncol 31:Abstract LBA9008
49. Eggermont A, Chairion-Sileni V, Grob JJ et al (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind phase 3 trial. Lancet Oncol 16:522–530
50. Jackson D, Greene J, Hale D et al (2015) Preclinical testing of a novel personalized cancer vaccine for all solid tumors and all patients. J ImmunoTherapy Cancer 3(Suppl 2):P208
51. Greene JM, Hale DF, Schneble EJ, et al. (2015) Initial phase I/IIa trial results of an autologous tumor lysate + yeast cell wall particles + dendritic cells vaccine (TLPLDC) in patients with solid tumors. In: CRI-CIMT-EATI-AACR: the inaugural international cancer immunotherapy conference: translating science into survival. New York. AACR:Abstract A044